⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Calliditas Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Calliditas Therapeutics
↗Stockholm, Sweden
Calliditas Therapeutics is a commercial-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for orphan indications, with an initial focus on renal and hepatic diseases. The company is known for its proprietary gut-targeted delivery platform (TARGIT), which aims to address disease drivers while minimizing systemic side effects.
Its lead product, TARPEYO (budesonide) delayed-release capsules, is the first FDA-approved, disease-modifying therapy for primary IgA nephropathy (IgAN). The company has expanded its reach through strategic partnerships and continues to advance a pipeline of candidates, including NOX inhibitors, for various rare diseases.
CLASSIFICATION
SIZE & FINANCIALS
Employees:101-500
Revenue:$100M-$200M
Founded:2004
Ownership:subsidiary
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$90M
Investors:Investinor
STOCK
Exchange:NASDAQ
Ticker:CALT
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule
Active Trials:14
Trial Phases:-
FDA Approvals:1
EMA Approvals:1
CORPORATE STRUCTURE
Parent Company:Asahi Kasei
Acquired By:Asahi Kasei (2024-05-01)
Key Partnerships:STADA (European commercialization of Kinpeygo)
COMPETITION
Position:Leader
Competitors:Hansa Biopharma, Travere Therapeutics, Novartis, Enyo Pharma, Arthrosi Therapeutics
LEADERSHIP
Key Executives:
Renée Aguiar-Lucander - CEO
LINKS
Website:calliditas.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Calliditas Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.